First experiences with the HeartWare ventricular assist system in children

Area of Science:

• Pediatric Cardiology
• Mechanical Circulatory Support
• Cardiac Transplantation

Background:

• Pediatric end-stage heart failure presents significant challenges.
• Ventricular assist devices (VADs) offer a potential solution for pediatric heart failure.
• Continuous flow VADs represent a newer generation of mechanical support.

Purpose of the Study:

• To evaluate the initial clinical experience with a new continuous flow VAD in pediatric patients.
• To assess the safety and efficacy of the HeartWare system as a bridge to transplantation in children.
• To describe outcomes in a cohort of pediatric patients requiring mechanical circulatory support.

Main Methods:

• A cohort of seven pediatric patients (aged 6-16 years) received the HeartWare VAD.
• The device was implanted as a bridge to cardiac transplantation.
• Patients were monitored for clinical outcomes, including bridging to transplant, device-related complications, and survival.

Main Results:

• All seven children presented with terminal heart failure and signs of organ impairment.
• Six patients (86%) were successfully bridged to cardiac transplantation.
• The median support duration was 75 days, with no reported thromboembolic events or infections.

Conclusions:

• The HeartWare continuous flow VAD is a viable and safe option for pediatric patients with end-stage heart failure.
• Successful bridging to transplantation was achieved in a majority of the pediatric cohort.
• This novel VAD system demonstrates promise in managing complex pediatric cardiac conditions.